

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumension Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**PATIENT ENROLLMENT COMPLETED IN THE REAL-WORLD STUDY**  
**OF OT-502 IN HAINAN BOAO**

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that OT-502 (dexamethasone implant), a new drug for the treatment of postoperative inflammation indication, has completed the enrollment of a total of 263 patients for the real-world study in Boao Lecheng International Medical Tourism Pilot Zone (博鳌樂城國際醫療旅遊先行區) in Hainan Province, the People’s Republic of China, among which 113 patients were in the experimental group and 150 patients were in the control group.

OT-502 (dexamethasone implant) is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperative inflammation. To date, OT-502 is the first and only single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration. The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China.

**Cautionary Statement:** The Company cannot guarantee that it will ultimately commercialize OT-502 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, August 14, 2023

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*